Limits...
The current state of proteomics in GI oncology.

Lin Y, Dynan WS, Lee JR, Zhu ZH, Schade RR - Dig. Dis. Sci. (2008)

Bottom Line: Proteomics refers to the study of the entire set of proteins in a given cell or tissue.In this article, we introduce the commonly adopted proteomic technologies and describe results of a comprehensive review of studies that have applied these technologies to GI oncology, with a particular emphasis on developments in the last 3 years.We discuss reasons why the more than 130 studies to date have had little discernible clinical impact, and we outline steps that may allow proteomics to realize its promise for early detection of disease, monitoring of disease recurrence, and identification of targets for individualized therapy.

View Article: PubMed Central - PubMed

Affiliation: Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, GA 30912, USA.

ABSTRACT
Proteomics refers to the study of the entire set of proteins in a given cell or tissue. With the extensive development of protein separation, mass spectrometry, and bioinformatics technologies, clinical proteomics has shown its potential as a powerful approach for biomarker discovery, particularly in the area of oncology. More than 130 exploratory studies have defined candidate markers in serum, gastrointestinal (GI) fluids, or cancer tissue. In this article, we introduce the commonly adopted proteomic technologies and describe results of a comprehensive review of studies that have applied these technologies to GI oncology, with a particular emphasis on developments in the last 3 years. We discuss reasons why the more than 130 studies to date have had little discernible clinical impact, and we outline steps that may allow proteomics to realize its promise for early detection of disease, monitoring of disease recurrence, and identification of targets for individualized therapy.

Show MeSH

Related in: MedlinePlus

Strategies for proteomic analysis of clinical samples. Samples may include serum, other body fluids, or tissue. Profiling may be antibody-based or MS-based. A variety of labeling and protein separation techniques may be used prior to the MS. Top-down and bottom-up approaches differ in the order in which steps are performed. In many proteomic studies, key findings are validated by independent means (see text for details and definition of additional terms)
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3045515&req=5

Fig1: Strategies for proteomic analysis of clinical samples. Samples may include serum, other body fluids, or tissue. Profiling may be antibody-based or MS-based. A variety of labeling and protein separation techniques may be used prior to the MS. Top-down and bottom-up approaches differ in the order in which steps are performed. In many proteomic studies, key findings are validated by independent means (see text for details and definition of additional terms)

Mentions: Figure 1 provides an overview of currently available analytical strategies, including types of samples and profiling methods.Fig. 1


The current state of proteomics in GI oncology.

Lin Y, Dynan WS, Lee JR, Zhu ZH, Schade RR - Dig. Dis. Sci. (2008)

Strategies for proteomic analysis of clinical samples. Samples may include serum, other body fluids, or tissue. Profiling may be antibody-based or MS-based. A variety of labeling and protein separation techniques may be used prior to the MS. Top-down and bottom-up approaches differ in the order in which steps are performed. In many proteomic studies, key findings are validated by independent means (see text for details and definition of additional terms)
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3045515&req=5

Fig1: Strategies for proteomic analysis of clinical samples. Samples may include serum, other body fluids, or tissue. Profiling may be antibody-based or MS-based. A variety of labeling and protein separation techniques may be used prior to the MS. Top-down and bottom-up approaches differ in the order in which steps are performed. In many proteomic studies, key findings are validated by independent means (see text for details and definition of additional terms)
Mentions: Figure 1 provides an overview of currently available analytical strategies, including types of samples and profiling methods.Fig. 1

Bottom Line: Proteomics refers to the study of the entire set of proteins in a given cell or tissue.In this article, we introduce the commonly adopted proteomic technologies and describe results of a comprehensive review of studies that have applied these technologies to GI oncology, with a particular emphasis on developments in the last 3 years.We discuss reasons why the more than 130 studies to date have had little discernible clinical impact, and we outline steps that may allow proteomics to realize its promise for early detection of disease, monitoring of disease recurrence, and identification of targets for individualized therapy.

View Article: PubMed Central - PubMed

Affiliation: Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, GA 30912, USA.

ABSTRACT
Proteomics refers to the study of the entire set of proteins in a given cell or tissue. With the extensive development of protein separation, mass spectrometry, and bioinformatics technologies, clinical proteomics has shown its potential as a powerful approach for biomarker discovery, particularly in the area of oncology. More than 130 exploratory studies have defined candidate markers in serum, gastrointestinal (GI) fluids, or cancer tissue. In this article, we introduce the commonly adopted proteomic technologies and describe results of a comprehensive review of studies that have applied these technologies to GI oncology, with a particular emphasis on developments in the last 3 years. We discuss reasons why the more than 130 studies to date have had little discernible clinical impact, and we outline steps that may allow proteomics to realize its promise for early detection of disease, monitoring of disease recurrence, and identification of targets for individualized therapy.

Show MeSH
Related in: MedlinePlus